S&P 500
5.011,12 -11,09 (-0,22%) Nasdaq
15.601,50 -81,87 (-0,52%) NIKKEI 225
37.103,99 -975,71 (-2,56%) Dólar/Euro
1,0641 -0,0006 (-0,05%) Petróleo Brent
89,12 +2,01 (+2,31%) Bitcoin EUR
58.895,77 +653,93 (+1,12%)
Amicus Therapeutics, Inc. (FOLD)
Después del cierre:
Amicus Therapeutics, Inc.
47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 517
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 984,09k | 461,21k | 1976 |
| Ms. Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 733,94k | N/A | 1963 |
| Mr. David M. Clark | Chief People Officer | 701,39k | N/A | 1975 |
| Dr. Jeffrey P. Castelli | Chief Development Officer | 709,64k | 88,61k | 1972 |
| Mr. Simon Nicolas Reade Harford | Chief Financial Officer | N/A | N/A | 1960 |
| Ms. Samantha Prout | Chief Accounting Officer & Controller | N/A | N/A | 1978 |
| Dr. Jill Weimer Ph.D. | Chief Science Officer | N/A | N/A | N/A |
| Andrew Faughnan | Senior Director of Investor Relations | N/A | N/A | N/A |
| Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | N/A | N/A | N/A |
| Ms. Diana Moore | Head of Global Corporate Communications | N/A | N/A | N/A |
Descripción
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Gobierno corporativo
El ISS Governance QualityScore de Amicus Therapeutics, Inc., a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 8; Tablero: 3; Derechos de los accionistas: 7; Compensación: 5.
